HCW Biologics Advanced Cancer Drug Candidate Plan
The Miramar-based firm has received FDA guidance for its upcoming clinical trial application.
Updated on Oct. 10, 2026 in Cancer
HCW Biologics is preparing an Investigational New Drug application for its lead cancer drug candidate, HCW11-018b. The Miramar company received regulatory guidance during a recent Type B meeting with the FDA.
Why it matters
The development aims to overcome the current limitations of bispecific T-Cell Engagers when treating solid tumors. This candidate utilizes a specialized non-Fc based platform to improve therapeutic effectiveness.
The drug candidate features an anti-CD3 single-chain antibody, soluble IL-15, and a TGF-beta receptor II domain trap. HCW Biologics currently has two licensing agreements for its proprietary molecules.
The players
HCW Biologics
This Miramar, Florida-based biopharmaceutical company focuses on discovering and developing novel immunotherapies to treat cancer.
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products.
The details
Manufacturing of cGMP material for clinical trials is already underway to support the upcoming application. HCW11-018b is the primary candidate within the company's T-Cell Engager Program, which leverages proprietary non-Fc based TRBC platform technology.
Timeline
March 31, 2026: The company filed its Form 10-K with the SEC.
October 9, 2026: The company announced progress on its IND application.
First half of 2027: The company plans to file the IND application.
The Big Picture
This development represents a significant step forward for the company's T-Cell Engager Program. It specifically aims to advance the clinical viability of non-Fc based platform technologies.
The progress of HCW11-018b could eventually provide new treatment options for patients facing solid tumors that current therapies struggle to address. Clinical trial availability remains the primary factor for future access to this experimental drug.
The takeaway
The development of new solid tumor therapies remains a highly complex process requiring multiple stages of regulatory clearance. Patients and caregivers should continue monitoring clinical trial listings for potential future enrollment opportunities.
What happens next
HCW Biologics is scheduled to file its formal Investigational New Drug application with federal regulators during the first half of 2027.
Further reading
Learn more about the latest research in this field at the Cancer section.
More information
View the current company clinical pipeline status for additional details on this program.
